Dyne Therapeutics, Inc. (NASDAQ:DYN - Get Free Report) insider Johanna Friedl-Naderer sold 900 shares of the business's stock in a transaction dated Friday, September 4th. The shares were sold at an average price of $24.35, for a total transaction of $21,915.00. Following the sale, the insider directly owned 153,082 shares of the company's stock, valued at approximately $3,727,546.70. This represents a 0.58% decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. The sale was made to cover tax withholding obligations related to the vesting of equity awards.
Johanna Friedl-Naderer also recently made the following trade(s):
- On Tuesday, September 8th, Johanna Friedl-Naderer sold 185 shares of Dyne Therapeutics stock. The stock was sold at an average price of $18.88, for a total transaction of $3,492.80.
Dyne Therapeutics Stock Performance
Shares of DYN stock opened at $20.31 on Wednesday. The company has a market cap of $3.79 billion, a P/E ratio of -6.10 and a beta of 1.08. The business has a 50 day moving average of $24.82 and a two-hundred day moving average of $20.49. Dyne Therapeutics, Inc. has a 52 week low of $11.92 and a 52 week high of $27.31. The company has a quick ratio of 12.02, a current ratio of 12.02 and a debt-to-equity ratio of 0.28.
Dyne Therapeutics (NASDAQ:DYN - Get Free Report) last announced its quarterly earnings results on Thursday, July 30th. The company reported ($1.08) earnings per share for the quarter, missing analysts' consensus estimates of ($0.75) by ($0.33). As a group, analysts anticipate that Dyne Therapeutics, Inc. will post -3.47 EPS for the current year.
Institutional Inflows and Outflows
A number of hedge funds have recently made changes to their positions in the stock. Handelsbanken Fonder AB acquired a new stake in Dyne Therapeutics in the second quarter worth approximately $1,182,000. Fisher Asset Management LLC acquired a new position in shares of Dyne Therapeutics during the 4th quarter valued at $4,891,000. Royal Bank of Canada increased its position in shares of Dyne Therapeutics by 267.6% during the 1st quarter. Royal Bank of Canada now owns 68,188 shares of the company's stock valued at $1,236,000 after purchasing an additional 49,641 shares during the period. Cibc World Market Inc. bought a new stake in shares of Dyne Therapeutics in the 4th quarter worth $1,345,000. Finally, Clearbridge Investments LLC bought a new stake in shares of Dyne Therapeutics in the 4th quarter worth $7,976,000. Institutional investors and hedge funds own 96.68% of the company's stock.
Dyne Therapeutics News Summary
Here are the key news stories impacting Dyne Therapeutics this week:
- Positive Sentiment: Dyne announced that it will present additional six- and 12-month data from the Phase 1/2 ACHIEVE trial of z-basivarsen (DYNE-101) at the World Muscle Society and AANEM meetings beginning September 29-30. The data will include comparisons with a matched natural-history cohort and updated safety results. Dyne ACHIEVE trial data announcement
- Positive Sentiment: The ACHIEVE registrational expansion cohort is fully enrolled, and Dyne expects topline results in the first quarter of 2027. DYNE-101 also has FDA Breakthrough Therapy, Orphan Drug and Fast Track designations, supporting the potential for an expedited development path. Quiver Quantitative ACHIEVE summary
- Neutral Sentiment: Call-option activity surged, with traders purchasing approximately 20,532 calls versus average daily volume of about 464. This may reflect speculative expectations for a rebound or upcoming data, but options activity does not confirm a fundamental improvement.
- Negative Sentiment: Reports said DYN fell heavily after a rival DM1 drug failed in Phase 3. Investors appear concerned that the setback could signal clinical or commercial risks for the DM1 field, even though Dyne’s own upcoming one-year data have not yet been released. RTT News report on rival DM1 failure
- Negative Sentiment: Several executives, including CEO John Cox, reported stock sales. The transactions were made to cover tax withholding on vested equity awards and were relatively small compared with their remaining holdings, limiting their direct significance, but the cluster of sales may add to cautious sentiment.
Wall Street Analysts Forecast Growth
DYN has been the subject of several analyst reports. Sanford C. Bernstein boosted their price target on shares of Dyne Therapeutics from $23.00 to $24.00 and gave the company a "market perform" rating in a report on Wednesday, May 13th. Evercore set a $33.00 target price on shares of Dyne Therapeutics in a research note on Friday, May 15th. Royal Bank Of Canada raised their price target on shares of Dyne Therapeutics from $30.00 to $35.00 and gave the company an "outperform" rating in a research note on Thursday, July 30th. Cantor Fitzgerald began coverage on Dyne Therapeutics in a report on Thursday, July 23rd. They set an "overweight" rating on the stock. Finally, Wall Street Zen downgraded Dyne Therapeutics from a "sell" rating to a "strong sell" rating in a research report on Saturday, August 1st. Two analysts have rated the stock with a Strong Buy rating, ten have assigned a Buy rating, two have issued a Hold rating and one has assigned a Sell rating to the stock. According to MarketBeat, the company presently has an average rating of "Moderate Buy" and a consensus price target of $34.17.
Get Our Latest Report on DYN
Dyne Therapeutics Company Profile
(
Get Free Report)
Dyne Therapeutics is a clinical-stage biotechnology company specializing in the development of localized gene regulation therapies for serious rare diseases. The company's proprietary FORCE (Facilitated Orthogonal Receptor‐mediated Cargo Evaluation) platform is designed to enable targeted delivery of oligonucleotide and gene therapy modalities to skeletal and respiratory muscles. Dyne's lead programs focus on Duchenne muscular dystrophy (DMD), myotonic dystrophy type 1 (DM1) and facioscapulohumeral muscular dystrophy (FSHD), with preclinical and early clinical studies evaluating safety, tolerability and tissue specificity.
Since its founding in 2019 by Flagship Pioneering, Dyne has advanced multiple product candidates using its modular delivery approach, which couples engineered ligands with therapeutic payloads to improve uptake into muscle cells.
Further Reading
This instant news alert was generated by narrative science technology and financial data from InsiderTrades.com in order to provide readers with the fastest and most accurate reporting. Please send any questions or comments about this story to [email protected].
